In a significant move aimed at easing the financial strain on families battling cancer, Finance Minister Nirmala Sitharaman announced in the Union Budget 2026-27 that the government will remove basic customs duty on 17 critical cancer drugs and medicines. The decision is designed to make life-saving therapies more affordable and improve access for patients dependent on imported treatments for complex and advanced cancers.
Customs Duty Exemption to Reduce Drug Costs
While presenting the Budget in Parliament, Sitharaman emphasized that the duty waiver would directly reduce the cost of essential oncology medicines. Imported cancer drugs often carry hefty customs duties, which significantly inflate retail prices. By eliminating this tax, the government expects the savings to reach patients, alleviating one of the largest financial burdens associated with cancer care.
“Even marginal reductions in medicine costs can make a substantial difference for families undergoing long treatment cycles,” noted healthcare experts. This move is especially critical for patients without comprehensive insurance coverage, who often face catastrophic out-of-pocket expenses.
Relief Extended to Rare Diseases
In addition to cancer drugs, the Budget also targets rare diseases. Finance Minister Sitharaman announced that seven more rare diseases will now qualify for customs duty exemptions. Patients importing specialized medicines, medical foods, or personalized therapies for these conditions will benefit from duty-free imports, reducing costs for treatments that are not manufactured domestically.
Rare disease medicines are often expensive due to small patient populations and high production costs. This exemption is expected to make these life-saving therapies more accessible and affordable for families who otherwise struggle to meet the financial demands of personalized care.
Impact on Patients and the Healthcare Sector
India has long faced challenges with the high cost of cancer treatment, with imported drugs forming a significant component of therapy. The removal of customs duties on 17 key cancer medicines is seen as a major step toward reducing financial stress on patients, particularly for those reliant on imported therapies for advanced cancers.
Officials clarified that the list of exempted drugs includes widely used, high-cost cancer medicines, though the full list has not yet been released. For rare diseases, which often lack Indian manufacturing alternatives, the measure is expected to significantly reduce landed costs, benefiting patients dependent on specialized treatments.
Balancing Affordability and Self-Reliance
The policy reflects the government’s broader commitment to healthcare affordability, while also promoting domestic pharmaceutical production. By targeting essential medicines for cancer and rare diseases, the Budget aims to strike a balance between immediate patient needs and long-term self-reliance goals.
Industry observers have welcomed the announcement as a direct and effective way to make medicines more affordable in the short term. However, experts caution that while drug costs may decrease, overall treatment expenses, covering hospital care, diagnostics, and supportive therapies, remain high, highlighting the need for a comprehensive healthcare financing strategy.
A Step Toward Patient-Centric Care
Despite these caveats, the customs duty exemptions on cancer drugs and expanded relief for rare disease therapies are among the most patient-focused measures in the Union Budget 2026-27. For thousands of families navigating the challenges of cancer and rare disease care, the policy offers real financial relief at a time of rising treatment costs, providing hope for more accessible and sustainable care options.
